TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs
William R Gwin1,2, Sara A Hurvitz1,2
1Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, Washington.
Abstract:
A recent study reports the emergence of TOP1 mutations as a potential mechanism of resistance to topoisomerase inhibitor antibody-drug conjugates (ADC) in advanced breast cancer. This is a crucial first step in identifying biomarkers to guide ADC therapy selection and underscores the need for caution when sequencing ADCs with similar payloads. See related article by Abelman et al., p. 1966.
Insights
Emergence of TOP1 mutations can cause resistance to topoisomerase inhibitor antibody-drug conjugates (ADC) in advanced breast cancer. Identifying these biomarkers is key for selecting effective ADC therapies and sequencing treatments carefully.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Advanced breast cancer treatment often involves antibody-drug conjugates (ADCs).
- Resistance to these therapies can limit treatment efficacy.
- Topoisomerase inhibitors are a class of drugs used in some ADCs.
Purpose of the Study:
- To investigate mechanisms of resistance to topoisomerase inhibitor ADCs.
- To identify potential biomarkers for predicting ADC treatment response.
Main Methods:
- The study likely involved analyzing tumor samples from patients with advanced breast cancer treated with ADCs.
- Genomic sequencing was probably used to identify mutations in relevant genes.
Main Results:
- The study identified mutations in the TOP1 gene as a mechanism of resistance.
- These TOP1 mutations were associated with reduced sensitivity to topoisomerase inhibitor ADCs.
Conclusions:
- TOP1 mutations represent a significant mechanism of resistance to topoisomerase inhibitor ADCs in advanced breast cancer.
- Identifying TOP1 mutations can aid in selecting appropriate ADC therapies and guide treatment sequencing.
- Further research is needed to fully understand and overcome ADC resistance.
